ProCE Banner Activity

First Clinical Study of CC-93269, a BCMA 2+1 T-Cell Engager, in Relapsed/Refractory Myeloma

Slideset Download
Conference Coverage
Initial results from ongoing phase I study suggest CC-93269 is safe with promising dose-dependent activity in heavily pretreated multiple myeloma.

Released: December 10, 2019

Expiration: December 08, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company